Journal Home
Search for

Volume 115, Issue 2, Pages 141-145 (December 2009)


View previous. 8 of 46 View next.

Biochemical risk factors for development of obesity in first-episode schizophrenia

Robert BodénaCorresponding Author Informationemail address, Arvo Haennib, Leif Lindströma, Johan Sundströmb

Received 29 May 2009; received in revised form 22 September 2009; accepted 24 September 2009. published online 22 October 2009.

Abstract 

Obesity is a serious health issue for many patients with schizophrenia. There is a lack of predictors for and understanding of the development of obesity in the early phase of the illness. Therefore we investigated a set of routine biochemistry variables in blood as predictors of the development of obesity and weight gain over 5years in an observational cohort study of patients with first-episode schizophrenia (n=59). Twelve percent of the patients were obese at baseline and 37% were obese at the 5-year follow-up. The mean body mass index (BMI) change over 5years was a 4.1kg/m2 increase (4.5 SD). Obesity was predicted by baseline hemoglobin levels (odds ratio per standard deviation [OR/SD] 3.3, 95% confidence interval [CI] 1.4 to 7.5), red blood cell count (OR/SD 2.6, 95% CI 1.2 to 5.5), hematocrit (OR/SD 2.8, 95% CI 1.3 to 5.9), γ-glutamyltransferase (OR/SD 2.8, 95% CI 1.2–6.3) and creatinine (OR/SD 3.1, 95% CI 1.2 to 8.0). After adjustment for baseline BMI, the associations were attenuated for γ-glutamyltransferase and creatinine. Low baseline BMI was associated with a greater BMI increase. The major conclusion is that easily available routine biochemistry markers can be useful in predicting the development of obesity in first-episode schizophrenia. The mechanisms underlying the observed associations are unknown, but the predictors identified in this study could signify dehydration or insulin resistance. These observations open a new window to future research on the mechanisms underlying the development of obesity in schizophrenia.

a Department of Neuroscience, Psychiatry Ulleråker, Uppsala University Hospital, S-750 17, Sweden

b Department of Medical Sciences, Uppsala University Hospital, S-751 85, Sweden

Corresponding Author InformationCorresponding author. Fax: +46 18 51 58 10.

 This report is written according to the STROBE guidelines.

PII: S0920-9964(09)00468-X

doi:10.1016/j.schres.2009.09.024


View previous. 8 of 46 View next.